Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. Januar 2019 16:15 ET | Quelle: Novan, Inc.

Novan Provides Business Update

End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early MarchActive business development discussions ongoing around certain late-stage assets and broader dermatology platformDr....
02. Januar 2019 06:15 ET | Quelle: Novan, Inc.

Novan Announces Management Changes and Provides Business Update

Paula Brown Stafford promoted to President and newly created role of Chief Operating Officer of Novan Dr. Carri Geer promoted to Senior Vice President and Chief Technology Officer Dr. Elizabeth...
11. Dezember 2018 08:00 ET | Quelle: Novan, Inc.

Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit

Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...
10. Dezember 2018 07:30 ET | Quelle: Novan, Inc.

Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily

SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05)Statistically significant reductions in molluscum lesions as early as Week...
20. November 2018 08:05 ET | Quelle: Novan, Inc.

Novan to Present at Piper Jaffray 30th Annual Healthcare Conference

MORRISVILLE, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Paula Brown Stafford, Chief Development Officer, and Nathan Stasko,...
14. November 2018 06:30 ET | Quelle: Novan, Inc.

Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results

Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
12. November 2018 08:05 ET | Quelle: Novan, Inc.

Novan Announces Corporate Update Conference Call and Webcast

MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at...
01. November 2018 08:05 ET | Quelle: Novan, Inc.

Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases

Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
25. Oktober 2018 07:05 ET | Quelle: Novan, Inc.

Novan Creates Dedicated Women’s Health Business Unit

Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
16. Oktober 2018 08:05 ET | Quelle: Novan, Inc.

Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation

External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...

Vorherige Seite